<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287963</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000454919</org_study_id>
    <secondary_id>MUSC-104864/725</secondary_id>
    <secondary_id>GSK-100780</secondary_id>
    <nct_id>NCT00287963</nct_id>
  </id_info>
  <brief_title>Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer</brief_title>
  <official_title>A Phase I Study of Topotecan in Combination With Vinorelbine in Recurrent Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as topotecan and vinorelbine, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of topotecan when&#xD;
      given together with vinorelbine in treating patients with recurrent lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of topotecan when combined with vinorelbine&#xD;
           ditartrate in patients with recurrent lung cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Assess the response and stable disease rates and the time to disease progression among&#xD;
           treated patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of topotecan.&#xD;
&#xD;
      Patents receive vinorelbine ditartrate IV over 8-10 minutes and topotecan IV over 30 minutes&#xD;
      on days 1 and 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which ≥ 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>Cycle 1 (up to day 21)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>while on study, at the end of each 3 week cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stable disease rate</measure>
    <time_frame>while on study, at the end of each 3 week cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>from start of treatment to day of documented progression or death, whichever comes first, up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Vinorelbine + topotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
    <arm_group_label>Vinorelbine + topotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate</intervention_name>
    <arm_group_label>Vinorelbine + topotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed lung cancer&#xD;
&#xD;
               -  All histologic types eligible&#xD;
&#xD;
               -  Recurrent or progressive disease after ≥ 1 prior chemotherapy regimen with or&#xD;
                  without radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status (PS) ≤ 2&#xD;
&#xD;
          -  Karnofsky PS ≥ 60%&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other active invasive malignancy&#xD;
&#xD;
          -  No uncontrolled illness including, but not limited to:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
          -  No psychiatric illness/social situation that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to topotecan or vinorelbine ditartrate&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior therapy with topotecan or vinorelbine ditartrate&#xD;
&#xD;
          -  No chemotherapy within the past 4 weeks (6 weeks for nitrosoureas or mitomycin C)&#xD;
&#xD;
          -  Recovered from agents administered &gt; 4 weeks earlier&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
&#xD;
          -  No other concurrent anticancer therapies or agents&#xD;
&#xD;
          -  No concurrent hormones or other chemotherapy except for the following:&#xD;
&#xD;
               -  Steroids for adrenal failure&#xD;
&#xD;
               -  Hormones for nondisease-related conditions (e.g., insulin for diabetes)&#xD;
&#xD;
               -  Intermittent dexamethasone as an antiemetic&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew S. Kraft, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gustavo Leone</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina, Hollings Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Beldner MA, Sherman CA, Green MR, Garrett-Mayer E, Chaudhary U, Meyer ML, Kraft AS, Montero AJ. Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer. 2007 Dec 20;7:231.</citation>
    <PMID>18096059</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>February 6, 2006</study_first_submitted>
  <study_first_submitted_qc>February 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2006</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>adenosquamous cell lung cancer</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <keyword>combined type small cell lung cancer</keyword>
  <keyword>intermediate type small cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>lymphocyte-like type small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

